[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"adverse-drug-reaction-adr\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:adverse-drug-reaction-adr":22},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,40,64,100,137],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":16,"targetDuration":4,"studyType":19,"phases":4,"briefSummary":20,"conditions":21,"keywords":23,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100381651","integrating-pediatric-pharmacogenomic-testing-into-the-canadian-health-care-system-100381651",false,"NCT04249375","Integrating Pediatric Pharmacogenomic Testing Into the Canadian Health Care System","Inclusion Criteria:\n\n* Participants will be enrolled if they can benefit from pharmacogenomic testing. This means their physician is considering the use of a drug that is part of the panels (analgesics, antibiotics, and mental health medication) or they are already using one.\n\nExclusion Criteria:\n\n* Patients who do not speak or understand English.","ALL",{"count":17,"type":18},150,"ESTIMATED","OBSERVATIONAL","This project addresses the problem of adverse drug reactions in the three most frequently prescribed therapeutic classes of drugs in children: antibiotics, analgesics, and mental health medications.\n\nWe will conduct pilot testing of a pharmacogenomic testing panel and study how the tests and generated test results are utilized and understood by physicians, pharmacists, patients and their families.",[22],"Adverse Drug Reaction (ADR)",[24,25,26],"Pharmacogenomics","Pediatrics","Adverse Drug Reactions","RECRUITING","2026-04-27",{"date":30,"type":31},"2026-05-01","ACTUAL",{"date":33,"type":31},"2020-02-20",{"date":35,"type":18},"2028-03",{"name":37,"class":38},"University of British Columbia","OTHER",2,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":47,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":19,"phases":4,"briefSummary":50,"conditions":51,"keywords":52,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":57,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":63},"100088734","national-active-surveillance-network-and-pharmacogenomics-of-adverse-drug-reactions-in-children-100088734","NCT00414115","National Active Surveillance Network and Pharmacogenomics of Adverse Drug Reactions in Children","Canadian Pharmacogenomics Network for Drug Safety","Inclusion Criteria:\n\n* Children under 19 years who have taken drugs.\n* Biological parents of children who have had an ADR.\n* Patients\u002Fparents who speak and understand English (except in Quebec).\n* Adults (for validation of findings in children)",true,{"count":49,"type":18},7000,"The purpose of the study is (1) to identify and collect samples from children and adults who take drugs and have adverse drug reactions AND children and adults who take drugs and do not experience any adverse drug effects; (2) to determine if genetic differences between the two groups contribute to causing the adverse drug reactions; and (3) to develop patient specific drug dosing guidelines to prevent future adverse drug reactions. We also wish to compare the use of prescription drugs, medical and hospital services and vital statistics between BC participants who experience adverse drug reactions and those who do not.\n\nStudy hypothesis: Genetic differences may contribute to patients' response to drugs and may be responsible for adverse drug reactions.",[22],[53,54,55,56],"Observational controlled study","Genomic biomarkers","Adverse drug reaction","In children OR adults",{"date":30,"type":31},{"date":59,"type":4},"2005-08",{"date":61,"type":18},"2029-03",{"name":37,"class":38},1,{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":15,"minAge":72,"maxAge":4,"enrollmentInfo":73,"targetDuration":75,"studyType":19,"phases":4,"briefSummary":76,"conditions":77,"keywords":86,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":63},"100571925","interprofessional-pharmacogenomics-ipgx-registry-and-repository-100571925","NCT06726590","Interprofessional Pharmacogenomics (IPGx) Registry and Repository","The Texas Interprofessional Pharmacogenomics Registry and Repository","IPGx Registry","Inclusion Criteria:\n\n* The study will invite patients who are eligible for PGX workup\u002FPGX care to participate, provided they meet the following criteria: Use of five or more medications, including over the counter drugs, supplements, natural products, cannabis products, or other recreational drugs, or\n* Individuals taking blood pressure or depression medications, even if less than five medications.\n* Ability to understand and give consent.\n* Able to consent to donate blood and\u002For urine samples and buccal swabs.\n* Able to answer detailed questionnaires, including quarterly questionnaires about ADRs, cognitive testing such as serial mini-mental status exams, and or quality of life questions.\n* Able to understand that their health record and changes in health status will be followed for a five-year period and shared in deidentified form with the research community.\n* All genders.\n* Any age over 18 years.\n\nExclusion Criteria:\n\n* Individuals admitted to hospice.\n* Declines to participate or interact with staff\u002Fshare their medical status.\n* A diagnosis of Alzheimer's disease or related dementias in a medical record as this indicates a progressive, debilitating condition that impairs memory, thought processes, and functioning.,\n* Individuals who are unable or unwilling to provide consent.\n* Unable to verbally communicate and comprehend English language","18 Years",{"count":74,"type":18},3000,"6 Months","This program collects genetic and health information to help doctors choose the right medications for patients.",[78,79,80,81,82,83,84,22,85],"Diabetes","Cholesterol","Cancer","Blood Pressure Disorders","Heart Disease","Respiratory Ilness","COPD","Poly Pharmacy",[87,88,89,90],"REGISTRY","REPOSITORY","POLYPHARMACY","ADVERSE DRUG REACTION","2025-09-05",{"date":93,"type":31},"2025-09-12",{"date":95,"type":18},"2025-11",{"date":97,"type":18},"2029-11",{"name":99,"class":38},"Texas A&M University",{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":15,"minAge":72,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":110,"phases":111,"briefSummary":113,"conditions":114,"keywords":118,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":39},"100587526","pharmacogenomics-supported-psychotropic-prescribing-trial-100587526","NCT06929533","Pharmacogenomics-Supported Psychotropic Prescribing Trial","Pharmacogenomics-Supported Psychotropic Prescribing Trial (PGx-SUPPORT): A Pilot Implementation Study in Manitoba","PGx-SUPPORT","Inclusion Criteria:\n\n* Aged 18 years or older\n* The initiation, change, dose adjustment, or augmentation of psychotropic medication(s) is indicated\n* The treating clinician thinks PGx testing can benefit and refers the patient to the study\n\nExclusion Criteria:\n\n* Unwillingness to donate saliva samples for genetic analysis\n* History of liver or bone marrow (hematopoietic cell) transplantation\n* PGx testing results are already available\n* No personal health identification number (PHIN) is available",{"count":109,"type":18},200,"INTERVENTIONAL",[112],"NA","Investigate the feasibility and utility of implementing pharmacogenetic testing for adults (aged 18 and older) seeking care for mental illness in Manitoba.",[115,116,22,117],"Mental Disorder","Pharmacogenetics","Effectiveness",[119,120,121,116,122,123,124,125,126,127],"Adult","Mental Health","Psychiatry","Depression","Anxiety","OCD","Psychosis","Bipolar Disorder","mental illness","2025-09-01",{"date":130,"type":31},"2025-09-08",{"date":132,"type":31},"2025-07-01",{"date":134,"type":18},"2030-12-31",{"name":136,"class":38},"University of Manitoba",{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":15,"minAge":72,"maxAge":144,"enrollmentInfo":145,"targetDuration":147,"studyType":19,"phases":4,"briefSummary":148,"conditions":149,"keywords":151,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":63},"100574960","ipgx-pilot-whole-genome-sequencing-extension-cohort-100574960","NCT06766071","IPGx PILOT Whole Genome Sequencing Extension Cohort","The Texas A&M Interprofessional Pharmacogenomics PILOT Whole Genome Sequencing (WGS) Cohort","Inclusion Criteria:\n\n* Individuals taking 5 or more medications, including over the counter drugs, supplements, natural products, cannabis produces, or other recreational drugs.\n* Ability to give and comprehend the consent process.\n* Consent to donate urine samples, genetic data through buccal swabs and blood samples, and undergo a comprehensive history and physical examination.\n* All genders\n* Age 18-100\n\nExclusion Criteria:\n\n* Subject has been diagnosed or is being treated for any cancer other than basal cell cancer in the last 5 years. Patients with metastatic melanoma in the last 5 years will be excluded.\n* Admitted to hospice.\n* Patient has ever been diagnosed with Hepatitis B or C.\n* Patient has ever been diagnosed with active liver disease, hepatomegaly, grossly abnormal liver function. Meld score \\>10, ALT, or AST \\>100U\u002FL or an AST\u002FALT ratio \\>2\n* Patients taking imidazole antifungal medication.\n* Declines to participate or interact with staff\u002Fshare their medical status.\n* A diagnosis of Alzheimer's disease or related dementias in a medical record indicates a progressive, debilitating condition that impairs memory, thought processes, and functioning.\n* Pregnant patients will be excluded.\n* Individuals who are unable or unwilling to provide consent will be excluded.\n* Unable to verbally communicate and comprehend English language.","100 Years",{"count":146,"type":18},50,"180 Days","The investigator's primary aim is to evaluate polypharmacy-associated adverse drug reactions (ADR) in a pilot study of at-risk patients using state-of-the-art pharmacogenomic technology and to use this information to make recommendations for optimization of pharmacotherapy regimens. The data from the pilot cohort will be used to optimize and integrate a customized electronic decision support (clinical semantic network; CSN) dashboard to identify drug regimens that should be modified, replaced, or discontinued. A secondary objective of the pilot study is to evaluate the capacity\u002Fsaturation of CYP P450 enzymatic pathways in polypharmacy patients. A third objective is to determine the feasibility of the planned informatics workflows between the CLIA lab, the EMR, and the Family Medicine Practice including Whole Genome Sequencing (WGS).",[22,150],"Polypharmacy Patients",[152],"whole genome sequencing","2025-01-03",{"date":155,"type":31},"2025-01-09",{"date":157,"type":18},"2025-01",{"date":159,"type":18},"2026-01",{"name":99,"class":38}]